Elevated Serum HMGB1 Levels and Their Association with Recurrence of Acute Ischaemic Stroke
Liping Shen,Jiangsheng Yang,Zufu Zhu,Weizhang Li,Junyou Cui,Lingyun Gu
DOI: https://doi.org/10.2147/jir.s477415
IF: 4.5
2024-10-01
Journal of Inflammation Research
Abstract:Liping Shen, Jiangsheng Yang, Zufu Zhu, Weizhang Li, Junyou Cui, Lingyun Gu Department of Neurology, Jiangyin Hospital Affiliated to Nantong University, Jiangyin, Jiangsu, People's Republic of China Correspondence: Lingyun Gu, Department of Neurology, Jiangyin Hospital Affiliated to Nantong University, 163 Shoushan Road, Jiangyin, Jiangsu, 214400, People's Republic of China, Tel/Fax +86 13915313817, Email Purpose: The study aimed to investigate the correlation between baseline serum levels of high mobility group box 1 (HMGB1) and the recurrence of acute ischemic stroke (AIS). Patients and Methods: A total of 544 AIS patients were enrolled and followed up monthly. Serum HMGB1 levels were measured using enzyme-linked immunosorbent assay (ELISA). The primary endpoint was the first recurrence of AIS. Results: During a median follow-up period of 43 months, 62 of the 544 AIS patients experienced a recurrence. Both HMGB1 levels and national institute of health stroke scale (NIHSS) scores were significantly higher in the recurrence group compared to the no-recurrence group (p< 0.05). According to the receiver operating characteristic curve analysis, the combination (0.855, 95% CI: 0.800– 0.911) of HMGB1 (0.745, 95% CI: 0.663– 0.826) and NIHSS (0.822, 95% CI: 0.758– 0.886) had a higher value for predicting AIS recurrence than either of them (p< 0.05). Kaplan-Meier analyses demonstrated that the cumulative survival without AIS recurrence was significantly lower in patients in the high HMGB1 level group than in the low HMGB1 level group (p< 0.05). The multifactorial Cox analyses indicated that elevated baseline serum HMGB1 levels (HR: 7.489, 95% CI:4.383– 12.795) were a highly effective predictor of recurrence in AIS. Conclusion: Elevated baseline serum HMGB1 levels were found to be a highly effective predictor of recurrence in AIS. Keywords: high mobility group box 1, acute ischemic stroke, recurrence The Global Burden of Disease Study 2019 showed a significant increase in annual stroke incidence and deaths from 1990 to 2019. 1 Stroke is the leading cause of death in China, with the overall prevalence, morbidity, and mortality of stroke among adults aged 40 years and older estimated to be 2.6%, 505.2/100,000 person-years, and 343.4/100,000 person-years in 2020, respectively. 2 Acute ischemic stroke (AIS), which accounts for more than 86.9% of stroke, has a high recurrence rate, with 3.6% and 5.6% recurrence rates at 3 months and 12 months, respectively. 3 Epidemiological findings suggest that the 1-year risk of recurrence of AIS is 7–13%, and its 10-year risk of recurrence approaches 40%. 4,5 A number of biomarkers have been found to predict recurrence of AIS, such as cyclophilin A, cystatin C, lipoprotein-associated phospholipase A2, and homocysteine. 6–9 However, some biomarkers have certain limitations in clinical application or controversial results in some studies. Therefore, accurate prediction of recurrence of AIS remains challenging. The occurrence of AIS induces inflammatory responses and oxidative stress, which directly or indirectly result in neuronal cell damage or death, thereby further exacerbating the condition. 10–12 In addition, it has been found that inflammatory responses and oxidative stress stimulate the release of high mobility group box 1 (HMGB1) from damaged or necrotic cells. 13,14 HMGB1 normally acts as a damage-associated molecular pattern molecule in the extracellular space, modulating the inflammatory response and oxidative stress through different pathways. 14,15 HMGB1 released after AIS was found to play a crucial role in both the early pathological damage process and the late promotion of brain tissue repair and remodeling. 16 A systematic review and meta-analysis including 28 studies found that patients with AIS exhibit elevated plasma HMGB1 levels, which are positively correlated with disease severity and infarct volume. 17 Furthermore, a study involving 132 patients with AIS after intravenous thrombolysis found that plasma HMGB1 levels peak 6 hours after thrombolytic therapy and were associated with a poor prognosis at 3 months. 18 Elevated baseline plasma HMGB1 levels were also an independent predictor of poor prognosis at 1 year after AIS. 19,20 These findings strongly support the importance of monitoring baseline HMGB1 levels in patients with AIS, especially for the assessment of disease severity and prognosis. Genetic analysis and follow-up of 871 patients with AIS revealed that HMGB1 polymorphisms were significantly associated with a high risk of ischemic stroke, in particular the HMGB1 rs1412125 polymorphism, which may be a new genetic biomarker and potential targ -Abstract Truncated-
immunology